STOCK TITAN

Aptorum Group (NASDAQ: APM) details DiamiR merger and S-4 filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Aptorum Group Limited filed a Form 6-K to update investors on its previously announced merger with DiamiR Biosciences Corp.. The filing explains that Aptorum will form a wholly owned Delaware subsidiary that will merge with and into DiamiR, leaving DiamiR as a wholly owned subsidiary of Aptorum after the merger.

The merger remains subject to Aptorum shareholder approval and other closing conditions set out in the Merger Agreement dated July 14, 2025. Aptorum also reports that it has filed a proxy statement/prospectus on Form S-4 with the SEC, which provides detailed information about Aptorum, DiamiR and the merger, including financial statements for both companies and transaction-related financial information.

This Form 6-K incorporates the S-4 and related exhibits by reference into Aptorum’s existing Form S-8 and Form F-3 registration statements, meaning those registration statements now include the merger-related disclosures. The filing also includes standard forward-looking statement cautions, emphasizing that expectations about the merger and future performance involve risks and uncertainties.

Positive

  • None.

Negative

  • None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

 

Commission File Number: 001-38764

 

Aptorum Group Limited

 

17 Hanover Square

London W1S 1BN, United Kingdom

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  ☒            Form 40-F  ☐

 

 

 

 

 

EXPLANATORY NOTE

 

As previously disclosed, Aptorum Group Limited, a Cayman Islands exempted company with limited liability (“Aptorum”, “APM,” “Aptorum Group” or the “Company”) and DiamiR Biosciences Corp., a Delaware corporation (“DiamiR”), entered into an Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”), pursuant to which, among other matters, Aptorum will form a direct, wholly owned subsidiary in the state of Delaware (“Merger Sub”), which will merge with and into DiamR, with DiamiR surviving as a wholly owned subsidiary of Aptorum, and the surviving corporation of the merger with the Merger Sub (the “Merger”); in addition to the requirement of obtaining Aptorum shareholder approval, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement.

 

The Company is furnishing this Form 6-K to disclose and attach and incorporated by reference herein the Company’s proxy statement/prospectus on Form S-4 it filed with the SEC on October 6, 2025, which disclosed information about Aptorum and DiamiR and the Merger, including respective financial statements of each company and financial statements related to the Merger.    

 

This Form 6-K (including the exhibits hereto) is hereby incorporated by reference into the registration statements of the Company on Form S-8 (Registration Number 333-232591) and Form F-3 (Registration Number 333-268873) and into each prospectus outstanding under the foregoing registration statements, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, without limitation, statements regarding the financial position, financial performance, business strategy, expectations of our business and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

 

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

1

 

 

Financial Statements and Exhibits.

 

Exhibits.

 

The following exhibits are attached.

 

Exhibit   Description
10.1   Merger Agreement by and between Aptorum and DiamiR, dated July 14, 2025 (incorporated by reference to the Current Report on Form 6-K filed on July 22, 2025)
99.1   Registration Statement on Form S-4
23.1   Consent of CBIZ CPAs P.C.
23.2   Consent of Marcum LLP
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: October 8, 2025

 

  Aptorum Group Limited
     
  By: /s/ Ian Huen
    Ian Huen
    Chief Executive Officer

 

3

FAQ

What merger does Aptorum Group Limited (APM) describe in this Form 6-K?

The Form 6-K describes a planned merger in which Aptorum will form a direct, wholly owned Delaware subsidiary that will merge with and into DiamiR Biosciences Corp., with DiamiR surviving as a wholly owned subsidiary of Aptorum.

What conditions must be satisfied before the Aptorum–DiamiR merger can close?

The merger requires Aptorum shareholder approval and the satisfaction or waiver of the other closing conditions set forth in the Agreement and Plan of Merger dated July 14, 2025.

What is the purpose of the Form S-4 mentioned in Aptorum’s Form 6-K?

The Form S-4 is a proxy statement/prospectus filed on October 6, 2025 that provides detailed information about Aptorum and DiamiR and the merger, including financial statements for each company and financial statements related to the merger.

How does this Form 6-K affect Aptorum’s existing registration statements?

This Form 6-K, including its exhibits, is incorporated by reference into Aptorum’s registration statements on Form S-8 (Registration Number 333-232591) and Form F-3 (Registration Number 333-268873), and into each prospectus outstanding under those registration statements.

What forward-looking statement cautions does Aptorum include in this Form 6-K?

Aptorum notes that the Form 6-K contains forward-looking statements about financial position, performance, business strategy and management plans, and it cautions that these are subject to risks and uncertainties that could cause actual results to differ materially, referring readers to the Risk Factors section in its Annual Report on Form 20-F.